Gal-Moscovici A, Gal M, Popovtzer M M
Nephrology and Hypertension Services, Hadassah University Hospital, Jerusalem, Israel.
Eur J Clin Invest. 2005 Jun;35(6):375-9. doi: 10.1111/j.1365-2362.2005.01503.x.
Antiresorptive therapeutic regimens are the mainstay of current management of osteoporosis. Treatments that are promoting new bone formation are less available and less affordable. Previous studies have suggested that 24,25(OH)(2)D(3) could enhance bone formation. The effect of 24,25(OH)(2)D(3) on bone formation in ovariectomized osteopenic rats (OVX) was evaluated in this study.
Mature Sabra rats were divided into two groups: sham-operated and OVX. Three months after surgery the OVX and sham-operated rats were divided into the following subgroups: (1) sham rats injected with vehicle, (2) sham rats injected with 24,25(OH)(2)D(3), (3) OVX rats injected with vehicle, and (4) OVX rats injected with 24,25(OH)(2)D(3). After 2 weeks' treatment, histomorphometry of the right tibiae was performed.
Ovariectomy resulted in a decrease in total bone volume (TBV/TV) and in bone formation (BFR/BS), P < 0.005 and P < 0.05 respectively, when compared with the sham-operated rats. Beside the decrease in TBV and BFR, the OVX rats showed an increase in osteoclastic bone resorption (P < 0.001 vs. sham). Administration of 24,25(OH)(2)D(3) was followed by an increase in all static and dynamic bone-forming parameters. The TBV/BV (P < 0.025), osteoblast surface (Ob.S/BS) (P < 0.001), as well as the BFR/BS (P < 0.005), increased in the OVX-treated group when compared with the OVX-untreated and sham-operated rats. This increment in bone formation was associated with a decrease in bone resorption (P < 0.001 in OVX-treated vs. OVX-untreated rats).
This study shows that 24,25(OH)(2)D(3) may be of benefit in experimental osteopenia following ovariectomy, both by suppressing osteoclastic hyperactivity and by stimulating bone formation.
抗吸收治疗方案是目前骨质疏松症管理的主要手段。促进新骨形成的治疗方法较少且价格昂贵。先前的研究表明，24,25(OH)₂D₃可增强骨形成。本研究评估了24,25(OH)₂D₃对去卵巢骨质疏松大鼠（OVX）骨形成的影响。
将成年Sabra大鼠分为两组：假手术组和去卵巢组。手术后三个月，将去卵巢大鼠和假手术大鼠分为以下亚组：（1）注射赋形剂的假手术大鼠，（2）注射24,25(OH)₂D₃的假手术大鼠，（3）注射赋形剂的去卵巢大鼠，（4）注射24,25(OH)₂D₃的去卵巢大鼠。治疗2周后，对右侧胫骨进行组织形态计量学分析。
与假手术大鼠相比，去卵巢导致总骨体积（TBV/TV）和骨形成（BFR/BS）降低，分别为P < 0.005和P < 0.05。除了TBV和BFR降低外，去卵巢大鼠的破骨细胞骨吸收增加（与假手术组相比，P < 0.001）。给予24,25(OH)₂D₃后，所有静态和动态骨形成参数均增加。与未治疗的去卵巢大鼠和假手术大鼠相比，治疗组去卵巢大鼠的TBV/BV（P < 0.025）、成骨细胞表面（Ob.S/BS）（P < 0.001）以及BFR/BS（P < 0.005）均增加。这种骨形成的增加与骨吸收的减少相关（治疗组去卵巢大鼠与未治疗组去卵巢大鼠相比，P < 0.001）。
本研究表明，24,25(OH)₂D₃可能对去卵巢后的实验性骨质减少有益，其作用机制包括抑制破骨细胞活性亢进和刺激骨形成。
